Effect of immunotherapy in myelitis with atopic diathesis

Hiroyuki Murai, Hajime Arahata, Manabu Osoegawa, Hirofumi Ochi, Motozumi Minohara, Takayuki Taniwaki, Shozo Tobimatsu, Futoshi Mihara, Yuko Tsuruta, Shoichi Inaba, Jun-Ichi Kira

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

A recent nationwide survey of myelitis with atopic diathesis in Japan disclosed that the disease frequently shows a chronic persistent course. A neuropathological study of the spinal cord also revealed chronic active inflammation. Since the effects of various immunotherapies have not been studied extensively in this condition, we evaluated the efficacies of various immunotherapies in patients with myelitis with atopic diathesis. Forty-two treatments in 26 patients with myelitis with atopic diathesis were retrospectively analyzed. One of the following therapies was administered: (1) corticosteroids (CS) (pulse therapy followed by oral administration with gradual tapering); (2) intravenous immunoglobulin (IVIG) (400 mg/kg/day for 5 consecutive days); (3) plasma exchanges (PE); or (4) PE followed by IVIG or CS (PE+IVIG/CS). The therapeutic efficacies were evaluated by thorough neurological examination and laboratory tests including MRI, somatosensory evoked potentials (SEPs) and motor evoked potentials (MEPs). Objective neurological findings improved in 89% of the PE group and 90% of the PE+IVIG/CS group, compared with only 72% of the CS and 60% of the IVIG groups. Improvement determined by laboratory tests was seen in 57% of the PE and 57% of the PE+IVIG/CS groups, compared with only 15% of the CS and none of the IVIG groups. Thus, the improvement rate determined by laboratory tests was significantly greater for therapies including PE than for those without PE (p=0.0187). These data suggest that immunotherapy is effective in myelitis with atopic diathesis despite a chronic persistent course, and that PE is the most beneficial immunotherapy.

Original languageEnglish
Pages (from-to)39-47
Number of pages9
JournalJournal of the Neurological Sciences
Volume227
Issue number1
DOIs
Publication statusPublished - Dec 15 2004

Fingerprint

Myelitis
Plasma Exchange
Disease Susceptibility
Immunotherapy
Intravenous Immunoglobulins
Adrenal Cortex Hormones
Therapeutics
Motor Evoked Potentials
Somatosensory Evoked Potentials
Neurologic Examination
Oral Administration
Spinal Cord
Japan

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Murai, H., Arahata, H., Osoegawa, M., Ochi, H., Minohara, M., Taniwaki, T., ... Kira, J-I. (2004). Effect of immunotherapy in myelitis with atopic diathesis. Journal of the Neurological Sciences, 227(1), 39-47. https://doi.org/10.1016/j.jns.2004.08.001

Effect of immunotherapy in myelitis with atopic diathesis. / Murai, Hiroyuki; Arahata, Hajime; Osoegawa, Manabu; Ochi, Hirofumi; Minohara, Motozumi; Taniwaki, Takayuki; Tobimatsu, Shozo; Mihara, Futoshi; Tsuruta, Yuko; Inaba, Shoichi; Kira, Jun-Ichi.

In: Journal of the Neurological Sciences, Vol. 227, No. 1, 15.12.2004, p. 39-47.

Research output: Contribution to journalArticle

Murai, H, Arahata, H, Osoegawa, M, Ochi, H, Minohara, M, Taniwaki, T, Tobimatsu, S, Mihara, F, Tsuruta, Y, Inaba, S & Kira, J-I 2004, 'Effect of immunotherapy in myelitis with atopic diathesis', Journal of the Neurological Sciences, vol. 227, no. 1, pp. 39-47. https://doi.org/10.1016/j.jns.2004.08.001
Murai H, Arahata H, Osoegawa M, Ochi H, Minohara M, Taniwaki T et al. Effect of immunotherapy in myelitis with atopic diathesis. Journal of the Neurological Sciences. 2004 Dec 15;227(1):39-47. https://doi.org/10.1016/j.jns.2004.08.001
Murai, Hiroyuki ; Arahata, Hajime ; Osoegawa, Manabu ; Ochi, Hirofumi ; Minohara, Motozumi ; Taniwaki, Takayuki ; Tobimatsu, Shozo ; Mihara, Futoshi ; Tsuruta, Yuko ; Inaba, Shoichi ; Kira, Jun-Ichi. / Effect of immunotherapy in myelitis with atopic diathesis. In: Journal of the Neurological Sciences. 2004 ; Vol. 227, No. 1. pp. 39-47.
@article{174d943e1df54115b73f084ea4e9eda5,
title = "Effect of immunotherapy in myelitis with atopic diathesis",
abstract = "A recent nationwide survey of myelitis with atopic diathesis in Japan disclosed that the disease frequently shows a chronic persistent course. A neuropathological study of the spinal cord also revealed chronic active inflammation. Since the effects of various immunotherapies have not been studied extensively in this condition, we evaluated the efficacies of various immunotherapies in patients with myelitis with atopic diathesis. Forty-two treatments in 26 patients with myelitis with atopic diathesis were retrospectively analyzed. One of the following therapies was administered: (1) corticosteroids (CS) (pulse therapy followed by oral administration with gradual tapering); (2) intravenous immunoglobulin (IVIG) (400 mg/kg/day for 5 consecutive days); (3) plasma exchanges (PE); or (4) PE followed by IVIG or CS (PE+IVIG/CS). The therapeutic efficacies were evaluated by thorough neurological examination and laboratory tests including MRI, somatosensory evoked potentials (SEPs) and motor evoked potentials (MEPs). Objective neurological findings improved in 89{\%} of the PE group and 90{\%} of the PE+IVIG/CS group, compared with only 72{\%} of the CS and 60{\%} of the IVIG groups. Improvement determined by laboratory tests was seen in 57{\%} of the PE and 57{\%} of the PE+IVIG/CS groups, compared with only 15{\%} of the CS and none of the IVIG groups. Thus, the improvement rate determined by laboratory tests was significantly greater for therapies including PE than for those without PE (p=0.0187). These data suggest that immunotherapy is effective in myelitis with atopic diathesis despite a chronic persistent course, and that PE is the most beneficial immunotherapy.",
author = "Hiroyuki Murai and Hajime Arahata and Manabu Osoegawa and Hirofumi Ochi and Motozumi Minohara and Takayuki Taniwaki and Shozo Tobimatsu and Futoshi Mihara and Yuko Tsuruta and Shoichi Inaba and Jun-Ichi Kira",
year = "2004",
month = "12",
day = "15",
doi = "10.1016/j.jns.2004.08.001",
language = "English",
volume = "227",
pages = "39--47",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Effect of immunotherapy in myelitis with atopic diathesis

AU - Murai, Hiroyuki

AU - Arahata, Hajime

AU - Osoegawa, Manabu

AU - Ochi, Hirofumi

AU - Minohara, Motozumi

AU - Taniwaki, Takayuki

AU - Tobimatsu, Shozo

AU - Mihara, Futoshi

AU - Tsuruta, Yuko

AU - Inaba, Shoichi

AU - Kira, Jun-Ichi

PY - 2004/12/15

Y1 - 2004/12/15

N2 - A recent nationwide survey of myelitis with atopic diathesis in Japan disclosed that the disease frequently shows a chronic persistent course. A neuropathological study of the spinal cord also revealed chronic active inflammation. Since the effects of various immunotherapies have not been studied extensively in this condition, we evaluated the efficacies of various immunotherapies in patients with myelitis with atopic diathesis. Forty-two treatments in 26 patients with myelitis with atopic diathesis were retrospectively analyzed. One of the following therapies was administered: (1) corticosteroids (CS) (pulse therapy followed by oral administration with gradual tapering); (2) intravenous immunoglobulin (IVIG) (400 mg/kg/day for 5 consecutive days); (3) plasma exchanges (PE); or (4) PE followed by IVIG or CS (PE+IVIG/CS). The therapeutic efficacies were evaluated by thorough neurological examination and laboratory tests including MRI, somatosensory evoked potentials (SEPs) and motor evoked potentials (MEPs). Objective neurological findings improved in 89% of the PE group and 90% of the PE+IVIG/CS group, compared with only 72% of the CS and 60% of the IVIG groups. Improvement determined by laboratory tests was seen in 57% of the PE and 57% of the PE+IVIG/CS groups, compared with only 15% of the CS and none of the IVIG groups. Thus, the improvement rate determined by laboratory tests was significantly greater for therapies including PE than for those without PE (p=0.0187). These data suggest that immunotherapy is effective in myelitis with atopic diathesis despite a chronic persistent course, and that PE is the most beneficial immunotherapy.

AB - A recent nationwide survey of myelitis with atopic diathesis in Japan disclosed that the disease frequently shows a chronic persistent course. A neuropathological study of the spinal cord also revealed chronic active inflammation. Since the effects of various immunotherapies have not been studied extensively in this condition, we evaluated the efficacies of various immunotherapies in patients with myelitis with atopic diathesis. Forty-two treatments in 26 patients with myelitis with atopic diathesis were retrospectively analyzed. One of the following therapies was administered: (1) corticosteroids (CS) (pulse therapy followed by oral administration with gradual tapering); (2) intravenous immunoglobulin (IVIG) (400 mg/kg/day for 5 consecutive days); (3) plasma exchanges (PE); or (4) PE followed by IVIG or CS (PE+IVIG/CS). The therapeutic efficacies were evaluated by thorough neurological examination and laboratory tests including MRI, somatosensory evoked potentials (SEPs) and motor evoked potentials (MEPs). Objective neurological findings improved in 89% of the PE group and 90% of the PE+IVIG/CS group, compared with only 72% of the CS and 60% of the IVIG groups. Improvement determined by laboratory tests was seen in 57% of the PE and 57% of the PE+IVIG/CS groups, compared with only 15% of the CS and none of the IVIG groups. Thus, the improvement rate determined by laboratory tests was significantly greater for therapies including PE than for those without PE (p=0.0187). These data suggest that immunotherapy is effective in myelitis with atopic diathesis despite a chronic persistent course, and that PE is the most beneficial immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=8544257023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8544257023&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2004.08.001

DO - 10.1016/j.jns.2004.08.001

M3 - Article

VL - 227

SP - 39

EP - 47

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1

ER -